Biocytogen (HKEX: 02315), a global biotech company dedicated to discovering and developing novel antibody therapeutics, announced the licensing of its fully human antibodies to ...

This article explores how broadly neutralizing antibodies are being researched, not only for their potential in the ...

CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, Jan. 10, 2025 /PRNewswire/ -- Harbour BioMed (HKEX: 02142, the ...

Biocytogen’s fully human antibody will support the development of SOT109, SOTIO’s new ADC candidate aimed at the treatment of colorectal cancer and other gastrointestinal (GI) cancers.

BEIJING & PRAGUE--(BUSINESS WIRE)--#ADC--Biocytogen (HKEX: 02315), a global biotech company dedicated to discovering and developing novel antibody therapeutics, announced the licensing of its fully ...

Dr. Saef Izzy, Associate Professor of Neurology at Harvard Medical School, commented, “Treatment with nasal anti-CD3 not only dampened microglial activation but also led to marked improvements in ...

Your body can produce an infinite number of binding sites to bind to antigens. Immunoglobulin G (IgG) accounts for around 75% of all antibodies in the human body. Depending on the antigen, IgG can ...

“The fully human monoclonal antibodies developed using our RenMab™ platform exhibit exceptional binding and internalization capabilities, along with excellent developability. By utilizing ...

New Activin R-based medications can emerge as perfect solutions for balancing weight loss and muscle building, making a ...

Alloy Therapeutics ("Alloy"), a biotechnology ecosystem company dedicated to democratizing access to cutting edge drug discovery technologies, announced today that it is launching a new ...